ClinicalTrials.gg
CompletedNCT04751266Updated Apr 19, 2022

Metal Contamination After Minimally Invasive Repair of Pectus Excavatum (MIRPE)

An observational study in Congenital Funnel Chest, sponsored by Dr. Caroline Fortmann. Completed. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by Dr. Caroline Fortmann · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
12 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether there is a metal wear debris after minimally invasive repair of pectus excavatum and if there's a clinical relevance. Our hypothesis is that the metal bar after minimally invasive repair of pectus excavatum leads to a locally and systemic immune reaction due to elevated metal contamination.

02

Conditions studied

  • Congenital Funnel Chest

Browse trials for

03

In context

Funnel Chest

79 studies on the registry are indexed under Funnel Chest; 10 are open to participants now.

This study's enrollment of 28 is below the median of 68 across 32 observational studies indexed under Funnel Chest.

Browse Funnel Chest studies →

Lead sponsor

This is the only study on the registry with Dr. Caroline Fortmann as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MIRPE

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with MIRPE

    first minimally invasive repair of pectus excavatum

    Procedure: minimally invasive repair of pectus excavatum

Interventions

  • Procedureminimally invasive repair of pectus excavatum

    substernal insertion of a metal bar

06

What researchers measure

Primary outcomes

  1. change of mean chromium values in blood (µg/l)

    measurement of: 1) chromium in blood (in µg/l) at the time points: 1. pre implantation 2. 4 weeks after implantation (to see change to baseline) 3. 1 year after implantation (to see change to baseline) 4. 2 years after implantation (to see change to baseline) 5. explantation (usually 3 years after implantation; to see change to baseline) 6. 6-12 months after explantation (to see change to explantation) We will compare the mean metal values at each time point post implantation with the mean metal values pre implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 4 years

  2. change of mean chromium values in urine (µg/l)

    measurement of: 2) chromium in urine (in µg/l) at the time points: 1. pre implantation 2. 4 weeks after implantation (to see change to baseline) 3. 1 year after implantation (to see change to baseline) 4. 2 years after implantation (to see change to baseline) 5. explantation (usually 3 years after implantation; to see change to baseline) 6. 6-12 months after explantation (to see change to explantation) We will compare the mean metal values at each time point post implantation with the mean metal values pre implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 4 years

  3. change of mean chromium values in tissue (µg/g)

    measurement of: 3) chromium in tissue (in µg/g) at the time points: 1. implantation 2. explantation (usually 3 years after implantation; to see change to baseline) We will compare the mean metal values at explantation with the mean metal values before implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 3 years

  4. change of mean nickel values in blood (µg/l)

    measurement of: 4) nickel in blood (in µg/l) at the time points: 1. pre implantation 2. 4 weeks after implantation (to see change to baseline) 3. 1 year after implantation (to see change to baseline) 4. 2 years after implantation (to see change to baseline) 5. explantation (usually 3 years after implantation; to see change to baseline) 6. 6-12 months after explantation (to see change to explantation) We will compare the mean metal values at each time point post implantation with the mean metal values pre implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 4 years

  5. change of mean nickel values in urine (µg/l)

    measurement of: 5) nickel in urine (in µg/l) at the time points: 1. pre implantation 2. 4 weeks after implantation (to see change to baseline) 3. 1 year after implantation (to see change to baseline) 4. 2 years after implantation (to see change to baseline) 5. explantation (usually 3 years after implantation; to see change to baseline) 6. 6-12 months after explantation (to see change to explantation) We will compare the mean metal values at each time point post implantation with the mean metal values pre implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 4 years

  6. change of mean nickel values in tissue (µg/g)

    measurement of: 6) nickel in tissue (in µg/g) at the time points: 1. implantation 2. explantation (usually 3 years after implantation; to see change to baseline) We will compare the mean metal values at explantation with the mean metal values before implantation. Clinical data like body weight etc. won't be relevant for the analysis.

    Time frame: 3 years

Secondary outcomes

  1. Observation of clinical reactions in correlation with elevated metal values

    observation (description) of clinical symptoms of a metal allergy like * local rash * lassitude * chest pain * tachycardia * Nausea * pleural effusion for the time the bar is in place (3 years) and the metal values are evaluated. -\> Then compare the mean metal values (see above) with the baseline and the other patients (with and/or without problems) No records when the patients don't have any problems.

    Time frame: 4 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04751266
Lead sponsor
Dr. Caroline Fortmann
Collaborators
Friedrich-Alexander-Universität Erlangen-Nürnberg
Responsible party
Dr. Caroline Fortmann (Principal Investigator, Hannover Medical School) — Sponsor-investigator
First posted
Feb 12, 2021
Start date
Mar 2015
Primary completion
Apr 2022
Completion
Apr 2022
Last update
Apr 19, 2022

Study contacts

Caroline Fortmann, MD
principal investigator · Department of Pediatric Surgery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion